Welcome

Our Mission

The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) is an international group of rheumatologists and immunologists with special interests in lupus who have been working together on lupus research since 1991. Our mission statement is:

Towards a better world for people with lupus through prevention and improved outcomes

Join us in our mission. We at SLICC, rely completely on the generosity and support of our donors and funders to continue our work.

SLICC developed the Damage Index – the only internationally accepted way of measuring the long-term effects of lupus and its treatment on the body. Without this index, it would be impossible to study those effects over time and compare them between different countries, geographies, and ethnic groups.

SLICC carried out the largest ever study of cancer in patients with lupus – this taught us that only some cancers are more likely to occur in patients with lupus and that the drugs commonly used to treat this disease do not significantly increase this risk of cancer.

But to continue our work, to answer the questions that patients with lupus are asking, we need to invest.

DONATE
History & Objectives

About SLICC

Since its inception over 25 years ago, SLICC has evolved into a dynamic and expanding research group helping to promote lupus research and collaboration between scientific investigators. Over its history, SLICC has contributed to the development of multiple standardized outcome measures to better characterize lupus activity and damage as well as its response to varying treatments.

ABOUT US
 
Current Activities

SLICC’s Research

SLICC is dedicated to generating new knowledge in the field of lupus, and translating these basic and clinical research discoveries into better health care practices and policies to help provide a healthier future for people diagnosed with lupus.

In 1998, the SLICC group established a longitudinal cohort of newly diagnosed patients with lupus (SLICC Inception Cohort) to better understand risk factors for atherosclerosis and metabolic syndrome, and characterize nervous system involvement.

Our current research activities are focused on atherosclerosis, nervous system involvement, lupus nephritis, and damage accrual, and their economic impact using the inception cohort. New initiatives include development of a pregnancy cohort and working group on microparticles as well as revision of the SLICC/American College of Rheumatology (ACR) Damage Index (SDI).

 
SLICC Group

Organizational Structure

SLICC consists of a Board of Directors and 3 standing committees.

View Governing Body
SLICC Group

Membership

SLICC is an international research organization with 54 members who, collectively, represent 43 academic medical centres across 16 countries and 5 continents.

VIEW MEMBERS
THE LATEST

NEWS & EVENTS

Mar 27, 2020

The COVID-19 Rheumatology Patient Experience Survey

Thank you again for supporting the COVID–19 Global Rheumatology Alliance! Today, we launched The COVID-19 Rheumatology Patient Experience Survey. This survey is for adult patients with a rheumatic illness or the parents of a child with a rheumatic illness. With this information, we hope to obtain insights about how best to prevent or treat COVID-19 as well as understand the challenges patients are facing in this uncertain time.

Mar 27, 2020

The COVID-19 Global Rheumatology Alliance: Provider-Entered Registry

Our mission is to create a secure, de-identified, international case reporting registry and curate and disseminate the outputs from that registry. It is our hope that the information collected will help guide rheumatology clinicians in assessing and treating patients with rheumatologic disease and in evaluating the risk of infection in patients on immunosuppression. We are asking that clinicians use this site to report any and all cases of COVID-19 in rheumatology patients, including those with mild or no symptoms. We anticipate that completion of the case report form will take 5-10 minutes and no protected health information is requested. We plan to use the relevant information from these cases to provide expeditious updates to the global rheumatology community. The success of this voluntary effort depends on our joint participation and the breadth of information collected. We ask that you share this site with your colleagues internationally and encourage reporting. We were inspired by our colleagues in the IBD community who have put forth the helpful https://covidibd.org/ registry and urge anyone with information about coronavirus cases in patients with IBD to use the case reporting form on that site. Thank you for your contribution to this important work. The COVID-19 Global Rheumatology Alliance Team

Mar 27, 2020

Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Monthly administration of anifrolumab resulted in a higher percentage of patients with a response (as defined by a composite end point) at week 52 than did placebo, in contrast to the findings of a similar phase 3 trial involving patients with SLE that had a different primary end point. The frequency of herpes zoster was higher with anifrolumab than with placebo.